EUVIMEDEUVIMED entdecken
Crossref

Ozureprubart, a next-gen anti-IgE antibody, inhibits IgE binding to FcαRI, dissociates FcαRI-bound IgE, and reduces FcαRI expression on basophils 2258455

Rachel Ames, Heather Milestone, Niloufar Ziari, Dirk Brockstedt, Paul Kassner

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Rachel Ames und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immunoglobulin E (IgE) plays a central role in the pathogenesis of allergic inflammatory diseases. Omalizumab, the only FDA-approved anti-IgE therapy currently available to patients, has been shown to be effective in treating moderate-to-severe persistent asthma, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and in reducing allergic reactions to accidental exposure to IgE allergens in food-allergic individuals, including anaphylaxis.

Methods

Ozureprubart (also known as JYB1904 and RPT904) is a next-generation, half-life extended, anti-IgE monoclonal antibody designed to target the same epitope as omalizumab that uses the YTE mutation (M252Y/S254T/T256E) to significantly increase half-life. Additional modifications resulted in increased binding avidity to IgE, improvement of antibody stability, and reduction of the potential for immunogenicity.

Results

We report here that ozureprubart shows a 2-to-3-fold increase in ability to block IgE binding to FcαRI compared with omalizumab. Additionally, ozureprubart, like omalizumab, dissociates IgE bound to FcαRI and reduces levels of receptor-bound IgE and FcαRI on basophils.

Conclusion

These data show that ozureprubart shares many of the mechanisms of action of omalizumab. In combination with its extended half-life, these properties give ozureprubart the potential to be an improved anti-IgE therapy. Ozureprubart is currently in Phase 2 clinical development for the treatment of food allergy*, asthma**, and CSU**. *Study sponsored by RAPT Therapeutics, Inc. **Studies sponsored by Shanghai Jeyou Pharmaceutical Co., Ltd. in China Funding Source n/a Topic Categories Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)

Zitieren

APA

Ames, R., Milestone, H., Ziari, N., Brockstedt, D., & Kassner, P. (2026). Ozureprubart, a next-gen anti-IgE antibody, inhibits IgE binding to FcαRI, dissociates FcαRI-bound IgE, and reduces FcαRI expression on basophils 2258455. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.594

Vancouver

Ames R, Milestone H, Ziari N, Brockstedt D, Kassner P. Ozureprubart, a next-gen anti-IgE antibody, inhibits IgE binding to FcαRI, dissociates FcαRI-bound IgE, and reduces FcαRI expression on basophils 2258455. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.594

BibTeX
@article{Ames2026,
  author = {Ames, Rachel and Milestone, Heather and Ziari, Niloufar and Brockstedt, Dirk and Kassner, Paul},
  title = {Ozureprubart, a next-gen anti-IgE antibody, inhibits IgE binding to FcαRI, dissociates FcαRI-bound IgE, and reduces FcαRI expression on basophils 2258455},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.594}
}
Kostenlos starten →